Follow-up in melanoma patients

Due to lack of evidence from prospective clinical trials, the diagnostic procedures, their frequency, as well as the length of the follow-up period in cutaneous melanoma patients should be based on the individual risk of disease recurrence, which is strongly dependent on the stage of disease at the...

Descripción completa

Detalles Bibliográficos
Autores principales: Rutkowski, Piotr, Ługowska, Iwona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2014
Materias:
Short Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4101246/
https://www.ncbi.nlm.nih.gov/pubmed/25089158
http://dx.doi.org/10.1007/s12254-014-0151-y
_version_ 1782480854341124096
author Rutkowski, Piotr
Ługowska, Iwona
author_facet Rutkowski, Piotr
Ługowska, Iwona
author_sort Rutkowski, Piotr
collection PubMed
description Due to lack of evidence from prospective clinical trials, the diagnostic procedures, their frequency, as well as the length of the follow-up period in cutaneous melanoma patients should be based on the individual risk of disease recurrence, which is strongly dependent on the stage of disease at the time of diagnosis. In the paper we propose the current recommendations for follow-up strategy. Nowadays, new effective treatment options with biological agents justify the closer monitoring of high risk melanoma patients.
format Online
Article
Text
id pubmed-4101246
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-41012462014-07-30 Follow-up in melanoma patients Rutkowski, Piotr Ługowska, Iwona Memo Short Review Due to lack of evidence from prospective clinical trials, the diagnostic procedures, their frequency, as well as the length of the follow-up period in cutaneous melanoma patients should be based on the individual risk of disease recurrence, which is strongly dependent on the stage of disease at the time of diagnosis. In the paper we propose the current recommendations for follow-up strategy. Nowadays, new effective treatment options with biological agents justify the closer monitoring of high risk melanoma patients. Springer Vienna 2014-06-24 2014 /pmc/articles/PMC4101246/ /pubmed/25089158 http://dx.doi.org/10.1007/s12254-014-0151-y Text en © The Author(s) 2014 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Short Review
Rutkowski, Piotr
Ługowska, Iwona
Follow-up in melanoma patients
title Follow-up in melanoma patients
title_full Follow-up in melanoma patients
title_fullStr Follow-up in melanoma patients
title_full_unstemmed Follow-up in melanoma patients
title_short Follow-up in melanoma patients
title_sort follow-up in melanoma patients
topic Short Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4101246/
https://www.ncbi.nlm.nih.gov/pubmed/25089158
http://dx.doi.org/10.1007/s12254-014-0151-y
work_keys_str_mv AT rutkowskipiotr followupinmelanomapatients
AT ługowskaiwona followupinmelanomapatients

Ejemplares similares